Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-738-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
No gene or chromosome mutation found in any of the tests.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June - August 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 liver microsomal fraction
- Test concentrations with justification for top dose:
- Pre-experiment
The toxicity of the test item was determined with tester strains TA 98 and TA 100 in a pre-experiment. Eight concentrations were tested for toxicity and induction of mutations with three plates each. The experimental conditions in this pre-experiment were the same as described below for the main experiment I (plate incorporation test).
Toxicity may be detected by a clearing or rather diminution of the background lawn or a reduction in the number of revertants down to a mutation factor of approximately ≤ 0.5 in relation to the solvent control.
The test item was tested in the pre-experiment with the following concentrations:
3.16, 10.0, 31.6, 100, 316, 1000, 2500 and 5000 µg/plate
Main experiment
The test item concentrations to be applied in the main experiments were chosen according to the results of the pre-experiment. 5000 µg/plate was selected as the maximum concentration. The concentration range covered two logarithmic decades. Two independent experiments were performed with the following concentrations: 3.16, 10.0, 31.6, 100, 316, 1000, 2500 and 5000 µg/plate
All concentrations used - per active ingredient (90%, conversion factor 1.1) - Vehicle / solvent:
- Aqua destillata
- Untreated negative controls:
- yes
- Remarks:
- A. dest., Eurofins Munich, Lot No. 170619, 170627,170710
- Negative solvent / vehicle controls:
- yes
- Remarks:
- A. dest., Eurofins Munich, Lot No. 170619, 170627,170710
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- methylmethanesulfonate
- other: 1. 4-nitro-o-phenylene-diamine; 2. 2-aminoanthracene
- Details on test system and experimental conditions:
- Bacteria
Five strains of S. typhimurium with the following characteristics were used:
TA 98: his D 3052; rfa-; uvrB-; R-factor: frame shift mutations
TA 100: his G 46; rfa-; uvrB-; R-factor: base-pair substitutions
TA 1535: his G 46; rfa-; uvrB-: base-pair substitutions
TA 1537: his C 3076; rfa-; uvrB-: frame shift mutations
TA 102: his G 428 (pAQ1); rfa-; R-factor: base-pair substitutions
Tester strains TA 98, TA 1535 and TA 102 were obtained from MOLTOX, INC., NC 28607, USA. Tester strains TA 100 and TA 1537 were obtained from Xenometrix AG, Switzerland. They were stored as stock cultures in ampoules with nutrient broth (OXOID) supplemented with DMSO (approx. 8% v/v) over liquid nitrogen.
Samples of each tester strain were grown by culturing for 12 h at 37 °C in Nutrient Broth to the late exponential or early stationary phase of growth (approx. 109 cells/mL). A solution of 125 µL ampicillin (10 mg/mL) (TA 98, TA 100, TA 102) was added in order to retain the phenotypic characteristics of the strain.
S9 Homogenate
The S9 liver microsomal fraction was prepared at Eurofins Munich and obtained from Trinova Biochem GmbH, Giessen, Germany. Male Wistar rats were induced with phenobarbital (80 mg/kg bw) and β-naphthoflavone (100 mg/kg bw) for three consecutive days by oral route (Eurofins Munich) and male Sprague Dawley rats were induced with phenobarbital / β-naphthoflavone (Trinova).
The following quality control determinations were performed by Eurofins Munich:
a) Biological activity in the Salmonella typhimurium assay using 2-aminoanthracene and benzo[a]pyrene
b) Sterility Test
A stock of the supernatant containing the microsomes was frozen in aliquots of 2 and 4 mL and stored at <= -75 °C.
The protein concentration in the S9 preparation was 34.2 mg/mL.
The following quality control determinations were performed by Trinova Biochem GmbH:
a) Alkoxyresorufin-0-dealkylase activities
b) Test for the presence of adventitious agents
c) Promutagen activation (including biological activity in the Salmonella typhimurium assay using 2-aminoanthracene and benzo[a]pyrene)
A stock of the supernatant containing the microsomes is frozen in aliquots of 5 mL and stored at <= -75 °C.
The protein concentration in the S9 preparation was 33.7 mg/mL. - Evaluation criteria:
- Evaluation of cytotoxicity
Cytotoxicity can be detected by a clearing or rather diminution of the background lawn (indicated as "N" or "B", respectively in the result tables) or a reduction in the number of revertants down to a mutation factor of approximately ≤ 0.5 in relation to the solvent control.
Evaluation of mutagenicity
The Mutation Factor is calculated by dividing the mean value of the revertant counts by the mean values of the solvent control (the exact and not the rounded values are used for calculation).
A test item is considered as mutagenic if:
- a clear and dose-related increase in the number of revertants occurs and/or
- a biologically relevant positive response for at least one of the dose groups occurs in at least one tester strain with or without metabolic activation.
A biologically relevant increase is described as follows:
- if in tester strains TA 98, TA 100 and TA 102 the number of reversions is at least twice as high
- if in tester strains TA 1535 and TA 1537 the number of reversions is at least three times higher than the reversion rate of the solvent control.
A test item producing neither a dose related increase in the number of revertants nor a reproducible biologically relevant positive response at any of the dose groups is considered to be non-mutagenic in this system. - Statistics:
- According to OECD guidelines, the biological relevance of the results is the criterion for the interpretation of results, a statistical evaluation of the results is not regarded as necessary.
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- During the described mutagenicity test and under the experimental conditions reported, the substance did not cause gene mutations by base pair changes or frameshifts in the genome of the tester strains used.
Therefore, it is considered to be non-mutagenic in this bacterial reverse mutation assay. - Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June 2017 - April 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- 29 July 2016
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- 30 May 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- lymphocytes:
- Details on mammalian cell type (if applicable):
- Human peripheral blood lymphocytes from healthy and non-smoking donors with no known recent exposure to genotoxic chemicals and radiation were used to examine the ability of chemicals to induce cytogenetic damage and thus to identify potential carcinogens or mutagens in vitro. For this study (in each experiment) blood was collected only from a single donor to reduce inter-individual variability.
Blood samples were drawn by venous puncture and collected in heparinized tubes. Before use the blood was stored under sterile conditions at 4 °C for a maximum of 4 h. Whole blood samples treated with an anti-coagulant (e. g. heparin) were pre-cultured in the presence of mitogen (phyto-haematogglutinin, PHA). - Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix
- Test concentrations with justification for top dose:
- Concentrations in the main experiment were selected based on the prelimnary experiment, where the following concentrations were tested: 5, 10, 25, 50, 100, 250, 500, 1000, 2500, 5000 ug/mL
Precipitation was observed at concentrations 1000 ug/mL and higher. Strong cytotoxicity was observed at 250 ug/mL
Main experiment:
Experiment I
without S9 mix: 1, 1.25, 5, 10, 25, 50, 100, 150, 200 ug/mL (microscopic analysis: 10, 25, 50 ug/mL)
with S9 mix: 2, 5, 10, 25, 50, 100, 150, 200, 250 ug/mL (microscopic analysis 10, 25, 50, 100 ug/mL)
Experiment II
without S9 mix: 10, 25, 50, 100, 150, 200, 250, 300, 500 ug/mL (microscopic analysis: 50, 100, 150 ug/mL)
All concentrations used - per active ingredient (90%, conversion factor 1.1) - Vehicle / solvent:
- RPMI cell culture medium
- Untreated negative controls:
- yes
- Remarks:
- treatment medium (complete culture medium without FBS)
- Negative solvent / vehicle controls:
- no
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- ethylmethanesulphonate
- Details on test system and experimental conditions:
- Complete Culture Medium:
RPMI 1640 medium supplemented with:
15 % fetal bovine serum (FBS)
100 U/100 µg/mL penicillin/streptomycin solution
0.24 g/mL PHA-L
Also used for the long-term treatment and the post incubation.
Treatment Medium (short-term exposure):
Complete culture medium without FBS.
All incubations were done at 37 °C in humidified atmosphere with 5% CO2.
Treatment:
Experiment I: Short-term exposure 4 h (without and with S9 mix)
After 48 h the culture medium was replaced with serum-free medium containing the test item (without metabolic activation) and serum-free medium containing the test item with 50 µL/mL S9 mix (with metabolic activation). After 4 h the cells were spun down by gentle centrifugation for 10 min. The supernatant with the dissolved test item was discarded and the cells were resuspended in PBS. The washing procedure was repeated once as described. After washing, the cells were resuspended in complete cell culture medium. The cells were prepared 24 h after the beginning of the treatment.
Experiment II: Long-term exposure 24 h (without S9 mix):
After 48 h the culture medium was replaced with complete medium (with 15% FBS) containing the test item without S9 mix. The treated cells were prepared at the end of the treatment.
For all experiments, the effect of the test item on cell cycle progression was investigated by addition of BrdU to the cultures. For each experiment the solvent and negative control and the highest dose group were evaluated to reassure the replication time of the cultured lymphocytes.
At least 2 h before harvesting, colcemid was added to the cultures (final concentration 0.2 µg/mL). The cultures were harvested by centrifugation 24 h after beginning of treatment. The supernatant was discarded and the cells were resuspended in approximately 5 mL hypotonic solution (0.4% KCl). The cell suspension was incubated at room temperature for 20 min. After removal of the hypotonic solution by centrifugation the cells were fixed with 3+1 methanol + glacial acetic acid. The fixation procedure was repeated twice. Slides were prepared by dropping the cell suspension onto a clean microscopic slide.The cells were stained with giemsa and according to the Fluorescent plus Giemsa technique, respectively.The slides were coverslipped using 2-3 drops of Eukitt(R). Afterwards they were air dried.
Analysis of metaphase cells:
All slides, including those of positive and negative controls were independently coded before microscopic analysis. Evaluation of the cultures was performed using microscopes with 100x oil immersion objectives. As structural chromosomal aberrations breaks, fragments, deletions, exchanges and chromosomal disintegrations were recorded. Gaps were recorded as well but not included in the calculation of the aberration rates. The definition of a gap was as follows: an achromatic region (occurring in one or both chromatids) independent of its width. The remaining visible chromosome regions should not be dislocated neither longitudinally nor laterally. At least, if available, 300 well spread metaphases per concentration and validity controls were scored for cytogenetic damage The number of metaphases scored can be reduced when high numbers of cells with chromosome aberration were observed and the chemical was considered as clearly positive. Metaphases with 46±2 centromeres regions were included in the analysis.
To describe a cytotoxic effect the mitotic index (% cells in mitosis; by counting the number of mitotic cells in 1000 cells) was determined. Additionally the number of polyploid cells was scored. Polyploid means a near tetraploid karyotype in the case of this aneuploid cell line. - Rationale for test conditions:
- Guideline study
- Evaluation criteria:
- Evaluation of results:
Providing that all acceptability criteria are fulfilled, a test chemical is considered to be clearly positive if, in any of the experimental conditions examined:
a) at least one of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control,
b) the increase is dose-related when evaluated with an appropriate trend test,
c) any of the results are outside the 95% control limits of the historical negative control data.
When all of these criteria are met, the test chemical is then considered able to induce chromosomal aberrations in cultured mammalian cells in this test system.
Providing that all acceptability criteria are fulfilled, a test chemical is considered clearly negative if, in all experimental conditions examined
a) none of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control,
b) there is no concentration-related increase when evaluated with an appropriate trend test,
c) all results are inside the 95% control limits of the historical negative control data.
The test chemical is then considered unable to induce chromosomal aberrations in cultured human peripheral blood lymphocyte cells in this test system. - Statistics:
- Biometry - Statistical significance at the 5% level (p < 0.05) was evaluated by the Fischer´s exact test. The p value was used as a limit in judging for significance levels in comparison with the corresponding negative control. Aberrant cells without gaps were only used for the calculation. Gaps are recorded separately and reported but generally not included in the total aberration frequency calculation according to the guideline.
Biometry - trend test - Statistical significance at the 5% level (p < 0.05) was evaluated by the ² test for trend. The p value was used as a limit in judging for significance levels. - Key result
- Species / strain:
- lymphocytes: Human peripheral blood lymphocytes
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- It can be stated that during the described in vitro chromosomal aberration test and under the experimental conditions reported, the test item did not induce structural chromosomal aberrations in human lymphocyte cells.
Therefore, the substance is considered to be non-clastogenic in this chromosome aberration test. - Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June-November 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 490 (In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene)
- Version / remarks:
- adopted July 29, 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial forward mutation assay
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Remarks:
- thymidine kinase locus
- Details on mammalian cell type (if applicable):
- clone TK+/- -3.7.2C
- Metabolic activation:
- with and without
- Metabolic activation system:
- Mammalian Microsomal Fraction S9 Homogenate
- Test concentrations with justification for top dose:
- The selection of the concentrations used in the main experiment was based on data from the pre-experiment. The test item was investigated at the following concentrations:
without metabolic activation:
60, 70, 75, 80, 85, 86, 87, µg/mL
and with metabolic activation:
104, 108, 112, 115, 118, 121, 124 µg/mL
All concentrations used - per active ingredient (90%, conversion factor 1.1) - Vehicle / solvent:
- RPMI cell culture medium (RPMI + 5% HS)
- Untreated negative controls:
- yes
- Remarks:
- treatment medium
- Negative solvent / vehicle controls:
- yes
- Remarks:
- the same as negative control
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- ethylmethanesulphonate
- methylmethanesulfonate
- Details on test system and experimental conditions:
- For a short-term exposure experiment 1 x 10^7 cells were suspended in 11 mL RPMI medium with 5% horse serum (25 cm2 flasks) and exposed to designated concentrations of the test item either in the presence or absence of metabolic activation in the mutation experiment. After 4 h the test item was removed by centrifugation (200 x g, 7 min) and the cells were washed twice with PBS. Subsequently the cells were suspended in 30 mL complete culture medium and incubated for an expression and growth period of 2 days in total at 37 °C in 5% CO2/95% humidified air. The cell density was determined each day and adjusted to 3 x 10^5 cells/mL in a total culture volume of 20 mL, if necessary.
After the expression period the cloning efficiency (CE) of the cells was determined by seeding a statistical number of 1.6 cells/well in two 96-well plates. The cells were incubated for at least 6 days at 37 °C in a humidified atmosphere with 5% CO2. Analysis of the results was based on the number of cultures with cell growth (positive wells) and those without cell growth (negative wells) compared to the total number of cultures seeded. Additionally, cultures were seeded in selective medium. Cells from each experimental group were seeded in four 96-well plates at a density of approximately 2000 cells/well in 200 µL selective medium with TFT. The plates were scored after an incubation period of about 12 days at 37 °C in 5% CO2/95% humidified air. - Rationale for test conditions:
- According to the OECD 490 Guideline.
- Evaluation criteria:
- Acceptability of the assay:
A mutation assay is considered acceptable if it meets the criteria mentioned in current international guidelines and the current recommendations of the IWGT:
- At least three out of four 96-well plates from the TFT resistance-testing portion of the experiment are scorable
- The cloning efficiency of the negative and/or solvent controls is in the range 65% -120%.
- The spontaneous mutant frequency in the negative and/or solvent controls is in the range 50-170 mutants per 106 cells
- The cell number of the negative/solvent controls should undergo 8-32 fold increase during a 2 day growth period (short-term treatment)
- The clastogenic positive controls (MMS and B[a]P) have to produce an induced mutant frequency (total mutant frequency minus concurrent negative control mutant frequency) of at least 300 mutants per 106 cells with at least 40% of the colonies being small colonies or with an induced small colony mutant frequency of at least 150 mutants per 106 cells The RTG must be greater than 10%.
Evaluation of results:
The test item is considered mutagenic if the following criteria are met:
- The induced mutant frequency meets or exceeds the Global Evaluation factor (GEF) of 126 mutants per 106 cells and
- a dose-dependent increase in mutant frequency is detected.
Besides, combined with a positive effect in the mutant frequency, an increased occurrence of small colonies (≥40% of total colonies) is an indication for potential clastogenic effects and/or chromosomal aberrations.
According to the OECD guideline, the biological relevance is considered first for the interpretation of results. Statistical methods might be used as an aid in evaluation of the test result.
A test item is considered to be negative if the induced mutant frequency is below the GEF and the trend of the test is negative. - Statistics:
- The mutant frequency was calculated by dividing the number of TFT resistant colonies by the number of cells plated for selection, corrected for the plating efficiency of cells from the same culture grown in the absence of TFT. For the microwell method used the Poisson distribution was used to calculate the plating efficiencies for cells cloned without and with TFT selection. Based on the null hypothesis of the Poisson distribution, the probable number of clones/well (P) is equal to
–ln(negative wells/total wells) and the plating efficiency (PE) equals P/(number of cells plated per well). Mutant frequency then was calculated as MF = (PE(cultures in selective medium)/PE(cultures in non-selective medium)). The mutant frequency is usually expressed as “mutants per 106 viable cells”.
Suspension growth (SG) of the cell cultures reflects the number of times the cell number increases from the starting cell density. When carrying out a short-term treatment (4 h) a 2-day growth period was considered. The relative total growth (RTG) is the product of the relative suspension growth (RSG; calculated by comparing the SG of the dose groups with the SG of the control) and the relative cloning efficiency (RCE) for each culture: RTG = RSG x RCE /100.
The mutant frequencies obtained from the experiments were compared with the Global Evaluation Factor (GEF). To arrive at a GEF, the workgroup (IWGT MLA Workgroup) analyzed distributions of negative/vehicle mutant frequencies of the MLA that they gathered from ten laboratories. The GEF is defined as the mean of the negative/vehicle mutant frequency plus one standard deviation. Applying this definition to the collected data, the GEF arrived to be 126 for the microwell method.
The non-parametric Mann-Whitney test was applied to the mutation data to prove the dose groups for any significant difference in mutant frequency compared to the negative/solvent controls. Mutant frequencies of the solvent/negative controls were used as reference. - Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- In the described mutagenicity test under the experimental conditions reported, the test item is considered to be non-mutagenic in the in vitro mammalian cell gene mutation assay (thymidine kinase locus) in mouse lymphoma L5178Y cells.
Referenceopen allclose all
Summary: Experiment I, without and with metabolic activation
Dose group |
Concen-tration [µg/mL] |
Relative Mitotic Index [%] |
Proliferation Index |
Mean % Aberrant Cells |
Historical Laboratory Negative Control Range |
Precipi-tation (+/-) |
Statistics |
||
incl. Gaps |
excl. Gaps |
||||||||
without 4 h treatment, 24 h preparation interval |
C |
0 |
100 |
1.35 |
3.7 |
2.7 |
-0.09 % – 3.47 % aberrant cells excl. gaps |
- |
/ |
4 |
10 |
40 |
/ |
4.7 |
2.6 |
- |
- |
||
5 |
25 |
60 |
/ |
5.0 |
4.7 |
- |
- |
||
6 |
50 |
53 |
1.20 |
3.7 |
2.0 |
- |
- |
||
EMS |
600 |
86 |
/ |
14.2 |
13.3 |
|
- |
+ |
|
|
|||||||||
with4 h treatment, 24 h preparation interval |
C |
0 |
100 |
1.37 |
2.3 |
1.3 |
-0.41 % – 3.42 % aberrant cells escl. gaps |
- |
/ |
3 |
10 |
107 |
/ |
4.0 |
1.3 |
- |
- |
||
4 |
25 |
64 |
/ |
0.7 |
0.3 |
- |
- |
||
5 |
50 |
74 |
/ |
1.7 |
0.3 |
- |
- |
||
6 |
100 |
42 |
1.45 |
2.6 |
2.6 |
- |
- |
||
CPA |
5 |
42 |
/ |
12.6 |
10.5 |
|
- |
+ |
The mitotic index was determined in 1000 cells per culture of each test group. The relative values of the mitotic index are related to the negative controls.
C: Negative Control (Culture Medium)
EMS: Ethylmethanesulfonate
CPA: Cyclophosphamide
a: - without precipitation. + with precipitation
b: statistical significant increase compared to negative controls (Fisher’s exact test, p< 0.05), +: significant; -not significant
Summary: Experiment II, without metabolic activation
Dose group |
Concen-tration [µg/mL] |
Relative Mitotic Index [%] |
Proliferation Index |
Mean % Aberrant Cells |
Historical Laboratory Negative Control Range |
Precipi-tation (+/-) |
Statistics |
||
incl. Gaps |
excl. Gaps |
||||||||
without 24 h treatment, 24 h preparation interval |
C |
0 |
100 |
/ |
4.3 |
2.7 |
-0.57 % - 3.16 % aberrant cells excl. gaps |
- |
/ |
3 |
50 |
100 |
/ |
4.0 |
1.7 |
- |
- |
||
4 |
100 |
65 |
/ |
4.3 |
2.7 |
- |
- |
||
5 |
150 |
52 |
/ |
6.0 |
3.0 |
- |
- |
||
EMS |
400 |
47 |
/ |
31.0 |
29.0 |
|
- |
+ |
The mitotic index was determined in 1000 cells per culture of each test group. The relative values of the mitotic index are related to the negative controls.
C: Negative Control (Culture Medium)
EMS: Ethylmethanesulfonate
a: - without precipitation. + with precipitation
b: statistical significant increase compared to negative controls (Fishers exact test, p< 0.05), +: significant; -not significant
Summary results, without and with metabolic activation
|
Test Group |
Conc. [µg/mL] |
RCEa[%] |
RTGb[%] |
MFc[mutants/ 106cells] |
IMFd[mutants/ 106cells] |
GEFeexceeded |
Statistical Significant Increasef |
Precipitate |
Exp without S9
|
C1 |
0 |
100.0 |
100.0 |
55.2 |
/ |
/ |
/ |
- |
C2 |
/ |
/ |
/ |
- |
|||||
2 |
60 |
103.4 |
115.6 |
67.1 |
11.9 |
- |
- |
- |
|
3 |
70 |
100.0 |
93.0 |
55.4 |
0.2 |
- |
- |
- |
|
4 |
75 |
105.1 |
73.0 |
53.8 |
-1.4 |
- |
- |
- |
|
5 |
80 |
105.1 |
49.6 |
51.1 |
-4.1 |
- |
- |
- |
|
10 |
85 |
110.7 |
18.2 |
52.5 |
-2.7 |
- |
- |
- |
|
11 |
86 |
110.7 |
23.9 |
47.3 |
-7.9 |
- |
- |
- |
|
12 |
87 |
110.7 |
14.5 |
58.8 |
3.6 |
- |
- |
- |
|
EMS |
300 |
62.1 |
54.6 |
1048.7 |
993.5 |
+ |
+ |
- |
|
MMS |
10 |
66.7 |
58.5 |
554.7 |
499.5 |
+ |
+ |
- |
|
|
|||||||||
Exp with S9
|
C1 |
0 |
100.0 |
100.0 |
55.4 |
/ |
/ |
/ |
|
C2 |
/ |
/ |
/ |
|
|||||
4 |
104 |
99.8 |
109.2 |
44.5 |
-10.9 |
- |
- |
|
|
5 |
108 |
93.8 |
76.0 |
44.3 |
-11.1 |
- |
- |
|
|
6 |
112 |
110.2 |
88.4 |
34.0 |
-21.5 |
- |
- |
|
|
7 |
115 |
110.2 |
59.9 |
38.9 |
-16.5 |
- |
- |
|
|
8 |
118 |
106.5 |
50.9 |
41.7 |
-13.7 |
- |
- |
|
|
9 |
121 |
93.8 |
30.6 |
38.1 |
-17.3 |
- |
- |
|
|
10 |
124 |
106.5 |
12.3 |
49.9 |
-5.5 |
- |
- |
|
|
B[a]P |
1.5 |
86.9 |
60.4 |
455.8 |
400.4 |
+ |
+ |
|
C: Negative Controls
a: Relative Cloning Efficiency, RCE = [(CEdose group/ CEof corresponding controls) x 100]
Cloning Efficiency, CE = ((-LN (((96 - (mean P1,P2)) / 96)) / 1.6) x 100)
b: Relative Total Growth, RTG = (RSG x RCE)/100
c: Mutant Frequency,
MF = {-ln [negative cultures/total wells (selective medium)] / -ln [negative cultures/total wells (non selective medium)]}x800
d: Induced Mutant Frequency, IMF = mutant frequency sample – mean value mutant frequency corresponding controls
e: Global Evaluation Factor, GEF (126); +: GEF exceeded, -: GEF not exceeded
f: statistical
significant increase in mutant frequency compared to negative controls
(Mann Whitney test , p<0.05).
+: significant; -not significant
EMS: Ethylmethanesulfonate
MMS: Methylmethanesulfonate
B[a]P: Benzo[a]pyrene
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Justification for classification or non-classification
No positive results in any of the performed gene/chromosome mutation tests.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
